<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Insulin-resistant states, such as <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, contribute substantially to accelerated atherogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>Null mutations of myostatin (Mstn) are associated with increased muscle mass and decreased fat mass </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we determined whether Mstn disruption could prevent the development of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, proatherogenic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and atherogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: C57BL/6 Ldlr(-/-) mice were cross-bred with C57BL/6 Mstn(-/-) mice for &gt;10 generations to generate Mstn(-/-)/Ldlr(-/-) double-knockout mice </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of high-fat/high-cholesterol diet on body composition, plasma <z:chebi fb="23" ids="18059">lipids</z:chebi>, systemic and tissue-specific insulin sensitivity, <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo>, as well as aortic atheromatous lesion were characterized in Mstn(-/-)/Ldlr(-/-) mice in comparison with control Mstn(+/+)/Ldlr(-/-) mice </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Compared with Mstn(+/+)/Ldlr(-/-) controls, Mstn(-/-)/ Ldlr(-/-) mice were resistant to diet-induced <z:hpo ids='HP_0001513'>obesity</z:hpo>, and had greatly improved insulin sensitivity, as indicated by 42% higher <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion rate and 90% greater muscle [(3)H]-2-<z:chebi fb="0" ids="15866">deoxyglucose</z:chebi> uptake during hyperinsulinemic-euglycemic clamp </plain></SENT>
<SENT sid="6" pm="."><plain>Mstn(-/-)/Ldlr(-/-) mice were protected against diet-induced <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> and had 56% higher rate of hepatic fatty acid beta-oxidation than controls </plain></SENT>
<SENT sid="7" pm="."><plain>Mstn(-/-)/Ldlr(-/-) mice also had 36% lower <z:chebi fb="1" ids="39027">VLDL</z:chebi> secretion rate and were protected against diet-induced <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, as indicated by 30-60% lower <z:chebi fb="1" ids="39027">VLDL</z:chebi> and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, free fatty acids, and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Magnetic resonance angiography and en face analyses demonstrated 41% reduction in aortic atheromatous lesions in Ldlr(-/-) mice with Mstn deletion </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Inactivation of Mstn protects against the development of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, proatherogenic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and aortic atherogenesis in Ldlr(-/-) mice </plain></SENT>
<SENT sid="10" pm="."><plain>Myostatin may be a useful target for drug development for prevention and treatment of <z:hpo ids='HP_0001513'>obesity</z:hpo> and its associated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>